Axa
TEVA icon

Axa’s Teva Pharmaceuticals TEVA Stock Holding History

Axa’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-238,989
Closed -$7.94M – 1362
2017
Q2 		$7.94M Buy
238,989
+1,476
+0.6% +$45.7K 0.04% 486
2017
Q1 		$7.62M Sell
237,513
-3,499
-1% -$119K 0.03% 495
2016
Q4 		$8.74M Sell
241,012
-377
-0.2% -$15.1K 0.04% 440
2016
Q3 		$11.1M Buy
241,389
+3,679
+2% +$192K 0.05% 368
2016
Q2 		$11.9M Buy
237,710
+36,088
+18% +$1.92M 0.05% 343
2016
Q1 		$10.8M Sell
201,622
-202
-0.1% -$11.9K 0.05% 377
2015
Q4 		$13.2M Buy
201,824
+2,674
+1% +$165K 0.06% 318
2015
Q3 		$11.2M Buy
199,150
+3,652
+2% +$237K 0.05% 355
2015
Q2 		$11.6M Buy
195,498
+2,233
+1% +$138K 0.05% 390
2015
Q1 		$12M Sell
193,265
-95,805
-33% -$5.57M 0.05% 363
2014
Q4 		$16.6M Buy
289,070
+4,002
+1% +$223K 0.07% 293
2014
Q3 		$15.3M Buy
285,068
+5,329
+2% +$282K 0.07% 294
2014
Q2 		$14.7M Buy
+279,739
New +$14.3M 0.06% 323
2013
Q3 		– Sell
-2,940
Closed -$115K – 1320
2013
Q2 		$115K Buy
+2,940
New +$114K ﹤0.01% 1145

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Axa's TEVA Position: Q3 2017 in Review

Axa sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 238,989 shares — an estimated $7.94M sold.

Axa first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $16.6M in Q4 2014. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Axa reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Axa sold 238,989 Teva Pharmaceuticals shares in Q3 2017, an estimated $7.94M.
  • Axa first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Axa's Teva Pharmaceuticals position peaked at $16.6M in Q4 2014.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Axa's 13F filing for Q3 2017, filed 13 Nov 2017.